Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Janssen’s new prostate cancer drug approved
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Jul 12, 2012 01:56:44
The Korea Food and Drug Administration approved Zytiga to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel chemotherapy, Janssen Korea said Wednesday.

In prostate cancer, the male sex hormone testosterone stimulates prostate tumors to grow. Drugs or surgery are used to reduce testosterone production or to block testosterone’s effects. However, sometimes prostate cancer can continue to grow even when testosterone levels are low. Men with these cancers are said to have castration-resistant prostate cancer.

According to clinical study of 1,195 patients with late-stage castration-resistant prostate cancer who had received prior treatment with docetaxel chemotherapy, patients receiving Zytiga and prednisone lived 4.6 months longer than those receiving a placebo and prednisone.

The U.S. FDA approved Zytiga in 2011. Zytiga is available in more than forty-five countries. Zytiga, generically known as abiraterone, should be combined with prednisone.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com